Dr Muttenthaler said there was an urgent need for new treatments for the chronic pain caused by gastrointestinal disorders such as irritable bowel syndrome (IBS) and irritable bowel diseases (IBD).

Hong Kong-based Insilico Medicine said its generative artificial intelligence (AI) platforms helped it design a molecule that ...

described as a next-generation antibody that binds to tumour necrosis factor-like ligand 1A (TL1A), which has emerged as a popular new target in IBD with several candidates in a race to market.

The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

The trial was investigating the use of vagus nerve stimulation (VNS) for inflammatory bowel disease (IBD), an autoimmune ...

More than half (62.7%) of respondents reported facing financial barriers to obtaining their IBD medication.

Inflammatory bowel disease (IBD) affects an estimated 1.6 million Americans. In fact, there are more than 70,000 new cases of ...

New Options Approved for Ulcerative Colitis ... Alternative trial designs should be considered for future novel drugs for IBD." Extended Benefit With Tulisokibart Long-term data from two clinical ...

The chronic condition can cause abdominal pain, diarrhea, bloody stools and fatigue. New research suggests it affects more ...

New Delhi: Inflammatory Bowel Disease (IBD) is a chronic condition characterized by ... Dr. Praveen Sharma described the ...

Hong Kong-based Insilico Medicine said its generative artificial intelligence (AI) platforms helped it design a molecule that showed promise in a new drug for treating inflammatory bowel disease ...